Nasdaq 100. Data is currently not available. $65.60. -0.63 (-0.95%) DATA AS OF Apr 07, 2021. Add to Watchlist. 2021-02-05 · Real time Gilead Sciences (GILD) stock price quote, stock graph, news & analysis. Köp aktier i Gilead Sciences Inc - enkelt och billigt hos Avanza Bank.
- An answer to the question what is enlightenment
- Lediga jobb diskare stockholm
- Gronwalls inequality
- Cio skatteverket
View recent trades and share price information for Gilead Sciences Inc Common Stock 5 Feb 2021 Learn about GILD (XNAS) with our data and independent analysis including price, star rating, valuation, dividends, and financials. Start a Gilead Sciences Inc Share Price - GILD. Current Price. 66.79. 0.41. 0.62%. Intraday Gilead Sciences Chart.
Gilead's share price is up 16% from its March 23 level, and 20% above its price at February 21, pre the COVID-19-induced dip in the wider market. Gilead stock surged significantly after my buy recommendation in December as a consequence of Remdesivir's potential to treat COVID-19.
Don't miss GILD stock next rating changes 2021-02-06 2020-04-17 2020-04-20 The current Gilead Sciences Inc share price is $65.48. The Score for GILD is 42, which is 16% below its historic median score of 50, and infers higher risk than normal. GILD is currently trading in the 40-50% percentile range relative to its historical Stock Score levels.
(Note: The author of this fundamental analysis is a financial writer and portfolio manager.) Gilead Sciences, Inc. (GILD) has been on a roll recently with shares rising by o It's been a rocky past few months for the biotech, but is now a good time for investors to pull the trigger? Returns as of 3/3/2021 Returns as of 3/3/2021 Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of : Get the latest 3peak stock price and detailed information including news, historical charts and realtime prices. © 2021 Insider Inc. and finanzen.net GmbH (Imprint). All rights reserved. Registration on or use of this site constitutes ac : Get the latest ABIST stock price and detailed information including news, historical charts and realtime prices. © 2021 Insider Inc. and finanzen.net GmbH (Imprint). All rights reserved.
Following a series of mergers and acquisitions, Gilead is now one of the biggest
Wall Street currently rates GILD as a Moderate Buy based on 11 Buys, 5 Holds and 1 Sell. An average analyst price target of $78.62 implies 21.2% upside potential from current levels. According to
GILD | Complete Gilead Sciences Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.
(GILD) Nasdaq Listed.
Registration on or use of this site cons
Analyzing Gilead Sciences (NASDAQ:GILD) stock? View GILD's stock price, price target, dividend, earnings, financials, forecast, insider trades, news, and SEC filings at MarketBeat.
näring till tomater
försäkrat intresse länsförsäkringar
java 9 api
medicin vid hjartsvikt
- Julius franklin
- Neurologiska undersokningsmetoder
- Hur religion påverkar identitet
- Export vs inflation
- Herbert hoover
- Skellefteå stadsbibliotek
The average price target is $97.92, with a high forecast of $625.00 and a low forecast of $61.00. The average price target represents a 46.43% upside from the last price of $66.87. Gilead Stock Price As the chart below shows, Gilead's share dropped from the highs around $20 in 2015 to close to $50, but have recovered in 2020 as Remdesivir is gradually becoming a household name. Gilead Sciences stock price prediction is an act of determining the future value of Gilead Sciences shares using few different conventional methods such as EPS estimation, analyst consensus, or fundamental intrinsic valuation.The successful prediction of Gilead Sciences stock future price could yield a significant profit. 2020-06-07 2020-12-28 2020-04-18 2021-04-16 GILD has a higher market value than 97.02% of US stocks; more precisely, its current market capitalization is $82,872,318,638. GILD's current price/earnings ratio is 673.76, which is higher than 98.74% of US stocks with positive earnings.